Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.
Dutch trial of convalescent plasma in COVID-19 discontinued

Dutch trial of convalescent plasma in COVID-19 discontinued

Does interferon therapy work in COVID-19?

Does interferon therapy work in COVID-19?

Potential targets discovered for COVID-19 therapy

Potential targets discovered for COVID-19 therapy

Antiviral cocktail may help treat mild COVID-19 patients

Antiviral cocktail may help treat mild COVID-19 patients

Experts advise not to make COVID-19 crisis worse by rushing for cures

Experts advise not to make COVID-19 crisis worse by rushing for cures

MU researcher finds four antiviral drugs effective in inhibiting novel coronavirus

MU researcher finds four antiviral drugs effective in inhibiting novel coronavirus

COVID-19 can trigger serious inflammatory-related cardiovascular problems

COVID-19 can trigger serious inflammatory-related cardiovascular problems

Remdesivir drug stops novel coronavirus from replicating

Remdesivir drug stops novel coronavirus from replicating

Patients with hypertension, diabetes and heart disease more likely to die from COVID-19

Patients with hypertension, diabetes and heart disease more likely to die from COVID-19

Updated USPSTF recommendations on hepatitis C screening

Updated USPSTF recommendations on hepatitis C screening

Researchers use big data to gain better understanding of hepatitis E virus

Researchers use big data to gain better understanding of hepatitis E virus

Measles can be deadly for people with weakened immune systems

Measles can be deadly for people with weakened immune systems

Researchers find possible active substance that may cure hepatitis E

Researchers find possible active substance that may cure hepatitis E

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Scientists find new clues to how RSV causes disease

Scientists find new clues to how RSV causes disease

Researchers study Lassa fever patient's immune response and viral persistence

Researchers study Lassa fever patient's immune response and viral persistence

FDA grants approval for two drugs to treat hepatitis C virus in children

FDA grants approval for two drugs to treat hepatitis C virus in children

Hepatitis C virus sabotages antiviral defenses of liver cells by blunting effect of immune proteins

Hepatitis C virus sabotages antiviral defenses of liver cells by blunting effect of immune proteins

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs

AbbVie's ABT-493 and ABT-530 achieve high SVR rates in GT1 chronic HCV patients who failed previous therapy with DAAs